Cheng Chun-Yuan, Lin Yi-Hsiang, Su Chin-Cheng
Institute of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan, R.O.C.
Mol Med Rep. 2009 Sep-Oct;2(5):707-11. doi: 10.3892/mmr_00000160.
Sann-Joong-Kuey-Jian-Tang (SJKJT), a traditional Chinese medicine, has been prescribed as complementary medication for colon cancer in Taiwan. However, its molecular mechanisms are not yet understood. In the present study, we investigated the effects of SJKJT on human colon cancer colo 205 cells in vitro. The cytotoxicity of SJKJT in colo 205 cells was evaluated using the MTT assay, and the protein expression of microtubule-associated protein II light chain 3 (MAP-LC3-II) was measured using Western blot analysis. The results showed that SJKJT inhibited the survival rates of colo 205 cells in a time- and dose-dependent manner, with an IC50 concentration at 24 h of 590.34 µg/ml. In addition, SJKJT up-regulated the protein expression of MAP-LC3-II in colo 205 cells. These findings indicate that one of the molecular mechanisms by which SJKJT inhibits the proliferation of colo 205 cells in?vitro may be through the induction of the autophagic pathway. SJKJT may therefore have therapeutic potential for the treatment of human colon cancer.
三黄桂枝汤(SJKJT)是一种中药,在台湾已被用作结肠癌的辅助药物。然而,其分子机制尚不清楚。在本研究中,我们在体外研究了SJKJT对人结肠癌colo 205细胞的影响。使用MTT法评估SJKJT对colo 205细胞的细胞毒性,并使用蛋白质印迹分析测量微管相关蛋白II轻链3(MAP-LC3-II)的蛋白表达。结果表明,SJKJT以时间和剂量依赖性方式抑制colo 205细胞的存活率,24小时的IC50浓度为590.34μg/ml。此外,SJKJT上调了colo 205细胞中MAP-LC3-II的蛋白表达。这些发现表明,SJKJT在体外抑制colo 205细胞增殖的分子机制之一可能是通过诱导自噬途径。因此,SJKJT可能具有治疗人类结肠癌的潜力。